Chest ACCP Career Connection
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Galgiani, J. N.
Right arrow Articles by Levine, H. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Galgiani, J. N.
Right arrow Articles by Levine, H. B.

Chest, Vol 86, 219-224, Copyright © 1984 by American College of Chest Physicians

ARTICLES

Pseudallescheria boydii infections treated with ketoconazole. Clinical evaluations of seven patients and in vitro susceptibility results

JN Galgiani, DA Stevens, JR Graybill, DL Stevens, AJ Tillinghast and HB Levine

Seven patients infected with Pseudallescheria boydii were treated with oral ketoconazole, 200 to 600 mg/day for one to 13 months. Five patients had pulmonary infections; two had skeletal infections. Improvement of pretreatment abnormalities occurred in five patients, one of whom had concurrent arthrodesis of his infected knee. The other two patients were subsequently healed by surgical resection of their pulmonary lesions. Ketoconazole appeared less active than miconazole against 22 clinical isolates of P boydii when tested by two in vitro methods. We conclude that ketoconazole is effective treatment for some patients infected with P boydii, although this may not be predicted by current in vitro susceptibility tests. Further experience is needed to establish the optimal use of ketoconazole with respect to its dosage, duration of administration and concurrent surgical resection.


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
G. M. Gonzalez, R. Tijerina, L. K. Najvar, R. Bocanegra, M. G. Rinaldi, D. Loebenberg, and J. R. Graybill
Activity of Posaconazole against Pseudallescheria boydii: In Vitro and In Vivo Assays
Antimicrob. Agents Chemother., April 1, 2003; 47(4): 1436 - 1438.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
M. Al Refai, C. Duhamel, J. P. Le Rochais, and P. Icard
Lung scedosporiosis: a differential diagnosis of aspergillosis
Eur. J. Cardiothorac. Surg., May 1, 2002; 21(5): 938 - 939.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Microbiol.Home page
E. C. M. Williamson, D. Speers, I. H. Arthur, G. Harnett, G. Ryan, and T. J. J. Inglis
Molecular Epidemiology of Scedosporium apiospermum Infection Determined by PCR Amplification of Ribosomal Intergenic Spacer Sequences in Patients with Chronic Lung Disease
J. Clin. Microbiol., January 1, 2001; 39(1): 47 - 50.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1984 by the American College of Chest Physicians.